CSIMarket
 
Ideaya Biosciences Inc   (NASDAQ: IDYA)
Other Ticker:  
 
 
Price: $22.1500 $0.72 3.360%
Day's High: $22.22 Week Perf: -2.85 %
Day's Low: $ 21.61 30 Day Perf: -0.58 %
Volume (M): 620 52 Wk High: $ 44.42
Volume (M$): $ 13,722 52 Wk Avg: $26.16
Open: $21.64 52 Wk Low: $13.45



 Market Capitalization (Millions $) 1,957
 Shares Outstanding (Millions) 88
 Employees 104
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -307
 Cash Flow (TTM) (Millions $) 22
 Capital Exp. (TTM) (Millions $) 4

Ideaya Biosciences Inc
Ideaya Biosciences Inc is a clinical-stage biotechnology company that focuses on the discovery and development of targeted therapeutics for patients with genomically defined cancers. The company utilizes its proprietary Synthetic Lethality Platform to identify and develop small molecules that can selectively target specific cancer-causing genetic alterations. By targeting these alterations, Ideaya aims to develop precise and effective treatments that can improve patient outcomes. The company is engaged in multiple clinical programs and collaborations with leading academic and pharmaceutical partners to advance its innovative pipeline of therapies.


   Company Address: 5000 Shoreline Court South San Francisco 94080 CA
   Company Phone Number: 443-6209   Stock Exchange / Ticker: NASDAQ IDYA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        2.5% 
BMY        0.66% 
ONC        11.53% 
PTGX        6.87% 
REGN   -3.49%    
VRTX        0.15% 
• View Complete Report
   



Business Update

In an exciting development for the pharmaceutical industry, IDEAYA Biosciences, Inc. (Nasdaq IDYA) has anno...

Published Wed, Nov 13 2024 10:29 PM UTC

Breaking Barriers: IDEAYA Biosciences Unveils Promising BsADC Candidate in Challenging Market Landscape In an exciting development for the pharmaceutical industry, IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has announced progress on its latest drug conjugate candidate, IDEAYAB7H3/PTK7 ADC (IDE034). This novel compound represents a groundbreaking advancement in the field of anti...

Business Update

IDEAYA Biosciences Advances B7H3/PTK7 Bispecific ADC Development with Biocytogen Collaboration Amidst Financial Chall...

Published Mon, Nov 11 2024 11:36 AM UTC

In a significant advancement within the biotechnology sector, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced that IDEAYA Biosciences, Inc. has exercised its option for an exclusive worldwide license regarding Biocytogen s promising B7H3/PTK7 bispecific antibody-drug conjugate (BsADC) programme, IDE034. This pivotal decision heralds the potential for IDE034 to be...

Business Update

IDEAYA Biosciences Develops Targeted B7H3/PTK7 Antibody-Drug Conjugate for Cancer Treatment

Published Thu, Aug 1 2024 6:28 AM UTC

IDEAYA Biosciences Advances Cancer Therapeutics with B7H3/PTK7-ADCIDEAYA Biosciences, Inc. (Nasdaq: IDYA) is making significant strides in the field of cancer therapeutics with its latest development of the B7H3/PTK7 antibody-drug conjugate (ADC), identified as ADC02315. This progressive approach leverages targeted therapy mechanisms to improve treatment outcomes for patien...

Business Update

Biocytogen and IDEAYA Biosciences Forge Partnership to Develop Pioneering B7H3/PTK7 Bispecific Antibody-Drug Conjug...

Published Wed, Jul 31 2024 10:47 AM UTC

In a significant move that promises to advance the field of targeted cancer therapies, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., recently announced an option and license agreement with IDEAYA Biosciences, Inc. This agreement centers around a groundbreaking bispecific antibody-drug conjugate (BsADC) program targeting B7H3 and PTK7, a combination that could set the stage...

Personnel Announcements

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Steer Corporate Strategy and Overcome Financial Challenges.

Published Tue, May 28 2024 10:00 AM UTC

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences, a precision medicine company specializing in oncology, has recently announced the appointment of Daniel A. Simon as the new Chief Business Officer. Simon brings with him extensive experience in the life sciences industry and strat...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com